Amicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest Update

Amicus Therapeutics, Inc. (NASDAQ:FOLD) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 19,600,000 shares, a drop of 5.9% from the November 30th total of 20,830,000 shares. Based on an average trading volume of 2,550,000 shares, the days-to-cover ratio is presently 7.7 days.

Insider Activity

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $11.46, for a total value of $85,950.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $10,161,054.84. This trade represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 22,901 shares of company stock worth $259,863. 2.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Amicus Therapeutics

A number of institutional investors have recently modified their holdings of the business. OLD Second National Bank of Aurora acquired a new position in Amicus Therapeutics during the third quarter worth $26,000. Hazlett Burt & Watson Inc. increased its stake in shares of Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 1,569 shares in the last quarter. Blue Trust Inc. lifted its stake in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI purchased a new position in Amicus Therapeutics in the 3rd quarter valued at about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Amicus Therapeutics in the 3rd quarter worth about $55,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on FOLD shares. Bank of America upped their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Jefferies Financial Group assumed coverage on Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 price objective for the company. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, November 7th. Finally, Cantor Fitzgerald lifted their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.88.

Amicus Therapeutics Stock Performance

NASDAQ FOLD traded up $0.01 during mid-day trading on Wednesday, reaching $9.42. 1,363,928 shares of the stock were exchanged, compared to its average volume of 2,690,285. The company has a market capitalization of $2.81 billion, a P/E ratio of -27.71 and a beta of 0.60. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The business’s 50 day moving average is $10.21 and its 200-day moving average is $10.57. Amicus Therapeutics has a 1 year low of $9.02 and a 1 year high of $14.53.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.